Podcast Medicom Medical Publishers

AAD Virtual Meeting Experience 2020 - Highlights

June 17, 2020 Medicom Medical Publishers
Podcast Medicom Medical Publishers
AAD Virtual Meeting Experience 2020 - Highlights
Chapters
0:17
Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020.
3:36
Khanna R, et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
6:10
Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020.
8:14
Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
11:08
Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
12:42
Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
Podcast Medicom Medical Publishers
AAD Virtual Meeting Experience 2020 - Highlights
Jun 17, 2020
Medicom Medical Publishers

Summary of articles from the AAD VMX 2020:

  1. Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020. 
  2. Khanna R et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
  3. Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020. 
  4. Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  5. Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  6. Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
Show Notes Chapter Markers

Summary of articles from the AAD VMX 2020:

  1. Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020. 
  2. Khanna R et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
  3. Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020. 
  4. Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  5. Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  6. Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020.
Khanna R, et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020.
Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.